Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines

Faust, Helena; Toft, Lars; Sehr, Peter; Müller, Martin; Bonde, Jesper; Forslund, Ola; Østergaard, Lars; Tolstrup, Martin; Dillner, Joakim

doi:10.1016/j.vaccine.2016.02.019

Cited by 40 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the studies on fibromyalgia, chronic pain with dysautonomia and CFS considered that a previous subclinical and spontaneous reaction to viral agents could be often involved in the start of pain and functional impairment. Therefore, a link between HPV vaccination and some neuromuscular and systemic impairment might be possible, considering also the immunization properties displayed by HPV vaccines, according to several studies [61]. …”

Section: Discussionmentioning

confidence: 99%

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

et al. 2016

View full text Add to dashboard Cite

Human papilloma virus (HPV) is recognized as a major cause for cervical cancer among women worldwide. Two HPV vaccines are currently available: Gardasil® and Cervarix®. Both vaccines enclose viral antigenic proteins, but differ as to the biological systems of culture and the adjuvant components. Recently, a collection of symptoms, indicating nervous system dysfunction, has been described after HPV vaccination. We retrospectively described a case series including 18 girls (aged 12–24 years) referred to our “Second Opinion Medical Network” for the evaluation of “neuropathy with autonomic dysfunction” after HPV vaccination. All girls complained of long-lasting and invalidating somatoform symptoms (including asthenia, headache, cognitive dysfunctions, myalgia, sinus tachycardia and skin rashes) that have developed 1–5 days (n = 11), 5–15 days (n = 5) and 15–20 days (n = 2) after the vaccination. These cases can be included in the recently described immune dysfunction named autoimmune/inflammatory syndrome induced by adjuvants (ASIA). HPV vaccine, through its adjuvant component, is speculated to induce an abnormal activation of the immune system, involving glia cells in the nervous system too. Further researches should aim at defining the pathological and clinical aspects of these post-vaccination diseases and identifying a genetic background predisposing to these adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Antibody titres for HPV 6/11/16/18, were 30–50% lower compared with historical age-matched controls, but higher than natural infections and in the range where clinical efficacy is seen in adults [60] . Studies in vertically-acquired HIV-positive adolescents adult men and women show high rates of seroconversion (95–100%), with no adverse effects on CD4 or plasma HIV RNA levels [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] . We currently await efficacy data, although 4vHPV vaccine will likely benefit immunocompromised men and women when vaccinated in the recommended age range, despite the lower titres seen in this population.…”

Section: Immunocompromised Hostsmentioning

confidence: 99%

HPV vaccination of immunocompromised hosts

Garland

Brotherton

Moscicki

et al. 2017

Papillomavirus Research

View full text Add to dashboard Cite

It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.

show abstract

“…Independent studies, considering early adolescent girls or HIV-positive individuals, have demonstrated that cross-neutralizing antibodies induced by the bivalent vaccine confer wider cross-neutralizing antibody response and wider protection against cervical hrHPV infections and associated intraepithelial lesions than the quadrivalent vaccine. [6][7][8] Also an independent study on vaccine-induced antibody sustainability in adolescent females found that bivalent vaccine-induced total HPV16 and HPV18 L1-VLP binding antibody levels were 5-and 18-fold (respectively) higher than those for the quadrivalent vaccine up to 12 years post vaccination. 9 The launching of a nonavalent HPV6/11/16/18/31/33/45/52/58 VLP vaccine to the market raises two pivotal questions for public health decision makers in respect to national vaccination programs: (1) how broad is the cross-neutralization ability of the bivalent vaccine-induced antibodies?…”

Section: Introductionmentioning

confidence: 99%

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

et al. 2020

Self Cite

View full text Add to dashboard Cite

We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.

show abstract

Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines

Cited by 40 publications

References 21 publications

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

HPV vaccination of immunocompromised hosts

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

Contact Info

Product

Resources

About